[The development of new drugs for acute stroke].
Stroke represents the third common cause of death and hospitalization. However, there are yet no drugs that have reliable effects on acute stroke in Japan. Therefore, the development of new drugs that can support patients is required. There are various candidate drugs for acute stroke such as antithrombotic agents, anticoagulants, thrombolytic agents, neuroprotectants, and so on. Recently clinical trials suggest that aspirin may improve outcome, although these studies demonstrated a modest benefit of aspirin. Abciximab (ReoPro) is a human/mouse monoclonal antibody directed against the platelet receptor glycoprotein IIb/IIIa. It appears to be safe and might improve functional outcome. The large randomized trails were started to test the hypothesis that thrombolysis by an intravenous administration of a recombinant tissue type plasminogen activator (rtPA) could restore cerebral blood flow and improve patient outcome in acute ischemic stroke. These results can support the use of intravenous rtPA for stroke treatment within 3 h after onset, but not beyond 3 h. Development of an effective neuroprotective agent for the treatment of acute stroke remains problematic. Antioxidants, MCI-186 and ebselen, have finished phase III of clinical trials in Japan and were effective. We hope that efficacious drugs for acute stroke can be used for patients.
Suzuki
Y
Y
Department of Pharmacology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu 431-3192, Japan.
Umemura
K
K
D000077284:Abciximab; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D000975:Antioxidants; D000983:Antipyrine / Q000031:analogs & derivatives*; D001241:Aspirin; D002986:Clinical Trials as Topic; D015195:Drug Design; D000077553:Edaravone; D005343:Fibrinolytic Agents; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D000975:Antioxidants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator; D001241:Aspirin; D000077553:Edaravone; D000983:Antipyrine; D000077284:Abciximab